



MAYNE PHARMA CONTINUES EXPANSION OF DERMATOLOGY PIPELINE

19 November 2019, Adelaide Australia: Mayne Pharma is pleased to announce it has licensed rights to a generic topical dermatology product from Encube Ethicals Pvt Ltd (Encube), a leading developer and manufacturer of topical formulations to distribute in the United States.

The product has a strong strategic fit with Mayne Pharma's existing portfolio of branded and generic dermatology products and was recently filed with the US Food and Drug Administration (FDA) with approval expected in calendar 2020. According to IQVIA, the annual market sales for this product were greater than US\$40m for the 12 months ending 30 September 2019.

Mayne Pharma's CEO, Mr Scott Richards said, "We are very pleased to have partnered with Encube who have an outstanding track record of innovative and generic topical drug development and operate one of the largest manufacturing facilities for topical prescription products globally. This is the third dermatology product we have licensed in FY20 leveraging our established sales and distribution capabilities in the dermatology space. The Company continues to have active discussions with a number of third parties, including Encube, around potential further product collaborations."

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, offering patients better and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world.

Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.